
Health Canada Approves Lilly's Omvoh® (mirikizumab) for Crohn's Disease; New Citrate-Free Formulation Français
In VIVID-1, Omvoh ® showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately to severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints. 3
Health Canada has also approved a new citrate-free formulation of Omvoh ® for subcutaneous injection, which contains the same active ingredients as the original Omvoh ®.
TORONTO, July 15, 2025 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh ® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh ® is an interleukin-23p19 antagonist for the treatment of adult patients with moderately to severely active CD who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment. 1 Health Canada has also approved a new citrate-free formulation of Omvoh ® for subcutaneous injection, for the existing UC indication, as well as the new CD indication.
"We are pleased to see that Omvoh ® will now be able to provide people living with moderately to severely active CD an effective and safe option for treatment," said Mathilde Merlet, President and General Manager of Lilly Canada. "With this additional indication, we are reinforcing our commitment to helping more of the IBD community. Additionally, we are proud to be able to introduce a new citrate-free formulation, which we hope will improve the patient experience, while offering the same quality, efficacy, and safety that patients are accustomed to."
The authorization of Omvoh ® for CD was based on results from the VIVID-1 clinical study, which included over 1,000 adults. In VIVID-1, mirikizumab showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately-to-severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints. The coprimary composite endpoints included patient-reported outcome (PRO) clinical response at week 12 and endoscopic response at week 52 (endoscopic response-composite), and PRO clinical response at week 12 and Crohn's Disease Activity Index (CDAI) clinical remission at week 52 (CDAI clinical remission-composite). Endoscopic response-composite was reached in 220 (38%) of 579 patients on mirikizumab versus 18 (9%) of 199 patients on placebo; CDAI clinical remission-composite was reached in 263 (45%) of 579 patients on mirikizumab versus 39 (20%) of 199 patients on placebo. Statistical significance was also observed in subgroups with and without failure to biological therapies for coprimary endpoints and most major secondary endpoints. 3
The Community Reacts:
Sylvain Chiasson, Interim President & CEO of Crohn's and Colitis Canada:
"Crohn's and Colitis Canada always welcomes new treatments for people with CD in Canada. CD is a chronic autoimmune disease where the immune system attacks the gastrointestinal system. CD is a complex disease that is debilitating, leads to hospitalizations and surgeries, and has a tremendous impact on the quality of life for the approximately 162,000 Canadians living with this disease. Because of the disease's complexity, not all people with CD respond in the same way to the available treatments. So, it is welcome news for Crohn's and Colitis Canada when there is a new therapy available for people with CD."
Gail Attara, Chief Executive Officer of the Gastrointestinal Society (www.badgut.org):
"We are so pleased to learn that Health Canada has approved a CD indication for Omvoh (mirikizumab). Compared to other inflammatory conditions, CD has very few medications, so the introduction of Omvoh's expanded use as a new option is excellent news for the IBD community."
Dr. John Marshall, Professor of Medicine, and Director of the Division of Gastroenterology at McMaster University:
"It is exciting to see a new and highly effective therapy being made available for people living with CD. Clinical trials have shown mirikizumab to be both safe and effective, and this will be an appealing treatment option for patients who are new to biologic therapies, or those who have not responded adequately to previous advanced therapies."
About the VIVID-1 Clinical Trial Program
VIVID-1 was a Phase 3, randomized, double-blind, treat-through study that evaluated the safety and efficacy of mirikizumab compared with placebo and an active control (ustekinumab) in adults with moderately to severely active CD. Patients randomized to mirikizumab were administered 900 mg of mirikizumab intravenously every four weeks from Weeks 0-8, then 300 mg subcutaneously every four weeks from Weeks 12-52. In this study, 49% of patients treated with mirikizumab or placebo had experienced a prior biologic failure. 2
The overall safety profile of mirikizumab in patients with moderately to severely active CD was consistent with the known safety profile in patients with UC. The frequency of serious adverse events was greater in placebo than mirikizumab. The most common adverse events were upper respiratory tract infections, injection site reactions, headache, and rash. 1
About Omvoh ®
Omvoh ® (mirikizumab) is an interleukin-23p19 (IL-23) antagonist indicated for the treatment of moderately to severely active UC and CD in adults. Omvoh ® selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to overactivation of the IL-23 pathway plays a critical role in the pathogenesis of CD, a chronic, IBD associated with progressive bowel damage, disability and decreased health-related quality of life.
For more information about Omvoh ®, please refer to the product monograph on Lilly.ca.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. Lilly has been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Lilly's Canadian Affiliate, Eli Lilly Canada Inc. was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world's first commercially available insulin.
Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
To learn more about Lilly Canada, visit Lilly.com/en-CA, or follow us on LinkedIn.
Omvoh ® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
7 hours ago
- Cision Canada
TALI AI JOINS QHR's MARKETPLACE TO BRING AI SCRIBING TO ACCURO®EMR USERS
TORONTO, July 24, 2025 /CNW/ - Tali AI, the leading Canadian healthtech company focused on reducing clinician burnout through AI-powered documentation, has joined QHR Technologies' Marketplace. Through an API integration with Accuro® EMR, Tali now enables users to streamline clinical documentation using a secure, real-time AI medical scribe. The integration allows Accuro users to launch Tali from within the EMR with synced authentication, view list of appointments in a side panel, and generate clinical notes from patient conversations all without switching tools. Tali also offers real-time medical dictation and AI-powered medical search trained on Canadian guidelines and drug monographs, providing clinicians with reliable, evidence-based answers in seconds. "We built Tali to leverage state of the art Generative AI models to support clinical workflows and reduce administrative burden at the point of care" said Mahshid Yassaei, CEO at Tali AI. "This integration with Accuro helps Canadian clinicians stay focused on patient care, while our AI handles the note-taking." Tali AI is SOC 2 Type II certified and compliant with PHIPA, PIPEDA, and all federal and provincial data privacy laws. It has been selected by provincial health bodies, including Canada Health Infoway and Supply Ontario, and ranked top 1% globally in terms of accuracy and note quality by the U.S. Department of Veterans Affairs. About Tali AI Tali AI is a Canadian company modernizing healthcare with trusted, responsible AI. Its AI Scribe supports clinicians across Canada and the U.S. with accurate, privacy-conscious tools that reduce documentation time and improve clinical workflows.


Toronto Star
8 hours ago
- Toronto Star
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2 Approval based on pivotal CABINET Phase III trial which demonstrated a 77% and 62% reduction in the risk of disease progression or death versus placebo in advanced pancreatic and extra-pancreatic neuroendocrine tumors, respectively3,4 PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.


Global News
9 hours ago
- Global News
Canada is facing a nationwide shortage of these prescription painkillers
A national shortage of common prescription pain medications in Canada could last into early August. Health Canada issued a notice last week that drugs containing acetaminophen with codeine or oxycodone that are used to relieve pain are experiencing shortages. Acetaminophen with oxycodone is often under the brand Percocet, while acetaminophen combined with codeine is sometimes known as Tylenol No. 3. Other formulations include Teva-Oxycocet, Teva-Lenoltic No. 1, 2, 3 and 4, and Rivacocet. Some of the companies that manufacture both medication combinations, including Teva Canada Ltd., Laboratoire Riva Inc. and Pharmascience Inc., have reported issues around manufacturing disruptions and increased demands as causes of the shortages. The Canadian Pharmacists Association told Global News it's been working with Health Canada and is in communication with manufacturers and suppliers to assess the potential impact. Story continues below advertisement 2:21 Another health care hurdle Prescription medication shortages In response to the shortages, the CPA said pharmacists have been limiting amounts given to patients. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'Usually pharmacists have to dispense the amount that is being written on the prescription unless it is being limited by the drug plan,' said Sadaf Faisal, senior director of professional affairs at the CPA. 'In a situation like these, pharmacists are documenting on their prescriptions that we are only supplying 30 days right now because we don't have enough supply.' She said some pharmacists are also seeking out supplies from other pharmacies. According to the association, the shortages are expected to last until early August, when a 'significant resupply' is anticipated. What Canadians can do if impacted In its notice, Health Canada said that as the shortage continues, Canadians should speak with their doctor or pharmacist if they have concerns about the availability of either medication. Story continues below advertisement It says they may be able to offer other options if their specific medication is not available. 'Pharmacists and other health-care providers can help them (patients) navigate this shortage,' Faisal said. 'We can identify alternatives, we can provide guidance on safe and effective pain management, which is really important because it can impact quality of life for a lot of patients.' Faisal does caution, however, that due to the Controlled Drugs and Substances Act, pharmacists cannot change the prescription or offer an alternative without consulting the physician to approve the suggestion. While the shortage may end within a few weeks, Health Canada is also urging Canadians to only use a licensed pharmacy to get medication and only buy products authorized for sale in Canada. It also advises people to avoid buying from unlicensed and unverified online sellers, as the products may not contain the active ingredient or contain undeclared and hazardous ingredients.